Crinetics Pharmaceuticals received FDA approval for Palsonify, a once-daily oral treatment for acromegaly, offering a new option for patients ineligible for or unresponsive to surgery. The therapy demonstrated significant reductions in growth hormone levels and a favorable safety profile in late-stage trials. Despite the drug's approval marking a major milestone for the company, it enters a market with established competitors from Novartis and Ipsen, indicating an upcoming contest among acromegaly therapies.